Sign up USA
Proactive Investors - Run By Investors For Investors

Time Warner and AT&T mega-deal approval bodes well for health care mergers, says Oppenheimer

CVS, Aetna and Express Scripts are trading higher after a federal judge allows AT&T to acquire Time Warner
CVS store
The CVS-Aetna deal and Cigna’s purchase of Express Scripts are similar to the AT&T-Time Warner tie-up

The proposed US$69bn tie-up between drugstore chain CVS Health Corp (NYSE:CVS) and the health insurer Aetna Inc (NYSE:AET) looks more likely to gain regulatory approval, Oppenheimer analysts say, in the wake of a federal judge’s historic ruling to allow AT&T Inc (NYSE:T) to go ahead with its herculean acquisition of Time Warner Inc (NYSE:TWX).

The fact that Judge Richard Leon threw out the US Justice Department’s move to block the US$85bn AT&T-Time Warner deal is pushing up shares of CVS and Aetna, as well as Express Scripts (NASDA:ESRX), which has reached a US$67bn deal to be acquired by the insurer Cigna (NYSE:CI).

Both the CVS-Aetna deal and Cigna’s purchase of Express Scripts (NASDAQ:ESRX) are similar to the tie-up between AT&T and Time Warner as they are vertical mergers, which involve two or more firms within a single supply chain combining.

Now under review by the Justice Department, CVS and Aetna’s tie-up is set to close in the second half of the year, while Cigna’s takeover of Express Scripts should be wound up by the year’s close.

“The closely watched trial was seen as a precedent case for CVS-Aetna and Cigna-Express Scripts,” wrote Oppenheimer analysts Mohan Naidu and Mike Ott in a note to investors. “We believe today’s decision should lift the stocks involved in CVS-Aetna and Cigna-Express Scripts as investor sentiment improves on the regulatory decision in these mergers.”

CVS announced its plans for the takeover of Aetna last December. Pending the approval of regulators, Aetna shareholders will receive US$145 per share in cash and 0.8378 CVS Health shares for each Aetna share.

Cigna, meanwhile, disclosed its agreement to purchase Express Scripts in March in a cash and stock transaction, which is worth about US$67bn and includes the taking on of about US$15bn in debt.

Express Scripts shares are up 4.6% at US$82.85 in morning trade; CVS is trading 3.6% higher at US$68.79; Aetna shares have jumped 4% to US$187.91; and Cigna shares are down slightly, losing 1.3% to hover at US$176.43.

The Justice Department's lawsuit to block the merger of AT&T and Time Warner was based on concerns that AT&T, which owns the satellite television group DirecTV, will be able exploit its market dominance and charge rival cable and satellite distributors higher fees, which will, in turn, hurt local customers.

View full AET profile View Profile

Aetna Timeline

Newswire
July 06 2015

Related Articles

numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use